Abstract
Tumor hypoxia is known to affect sensitivity to radiotherapy and promote development of metastases; therefore, the ability to image tumor hypoxia in vivo could provide useful prognostic information and help tailor therapy. We previously demonstrated in vitro evidence for selective accumulation of a gadolinium tetraazacyclododecanetetraacetic acid monoamide conjugate of 2-nitroimidazole (GdDO3NI), a magnetic resonance imaging T 1-shortening agent, in hypoxic cells grown in tissue culture. We now report evidence for accumulation of GdDO3NI in hypoxic tumor tissue in vivo. Our data show that GdDO3NI accumulated significantly (p < 0.05) in the central, poorly perfused regions of rat prostate adenocarcinoma AT1 tumors (threefold higher concentration than for the control agent) and showed better clearance from well-perfused regions and complete clearance from the surrounding muscle tissue. Inductively coupled plasma mass spectroscopy confirmed that more GdDO3NI than control agent was retained in the central region and that more GdDO3NI was retained in the central region than at the periphery. These results show the utility of GdDO3NI to image tumor hypoxia and highlight the potential of GdDO3NI for application to image-guided interventions for radiation therapy or hypoxia-activated chemotherapy.
Similar content being viewed by others
Abbreviations
- DOTA:
-
Tetraazacyclododecanetetraacetic acid
- GdDO3ABA:
-
Gadolinium tetraazacyclododecanetetraacetic acid (n-butyl)monoamide
- GdDO3NI:
-
Gadolinium tetraazacyclododecanetetraacetic acid monoamide conjugate of 2-nitroimidazole
- GdDTPA:
-
Gadolinium diethylenetriaminepentaacetic acid
- GdHPDO3A:
-
Gadolinium 10-(2-hydroxypropyl)-1,4,7-tetraazacyclododecane-1,4,7-triacetic acid
- ICP-MS:
-
Inductively coupled plasma mass spectrometry
- MR:
-
Magnetic resonance
- MRI:
-
Magnetic resonance imaging
- PET:
-
Positron emission tomography
References
Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D (2006) Int J Radiat Biol 82:699–757
Hockel M, Vaupel P (2001) J Natl Cancer Inst 93:266–276
Vaupel P, Mayer A (2007) Cancer Metastasis Rev 26:225–239
Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP (2012) Cancer Chemother Pharmacol 69:1487–1498
McKeage MJ, Jameson MB, Ramanathan RK, Rajendran J, Gu Y, Wilson WR, Melink TJ, Tchekmedyian NS (2012) BMC Cancer 12:496
Le QT, Fisher R, Oliner KS, Young RJ, Cao H, Kong C, Graves E, Hicks RJ, McArthur GA, Peters L, O’Sullivan B, Giaccia A, Rischin D (2012) Clin Cancer Res 18:1798–1807
He F, Deng X, Wen B, Liu Y, Sun X, Xing L, Minami A, Huang Y, Chen Q, Zanzonico PB, Ling CC, Li GC (2008) Cancer Res 68:8597–8606
Russell J, Carlin S, Burke SA, Wen B, Yang KM, Ling CC (2009) Int J Radiat Oncol Biol Phys 73:1177–1186
Griffiths JR, Robinson SP (1999) Br J Radiol 72:627–630
Krohn KA, Link JM, Mason RP (2008) J Nucl Med 49(Suppl 2):129S–148S
Mason RP, Zhao D, Pacheco-Torres J, Cui W, Kodibagkar VD, Gulaka PK, Hao G, Thorpe P, Hahn EW, Peschke P (2010) Q J Nucl Med Mol Imaging 54:259–280
Zhao D, Jiang L, Mason RP (2004) Methods Enzymol 386:378–418
Takahashi E, Takano T, Nomura Y, Okano S, Nakajima O, Sato M (2006) Am J Physiol Cell Physiol 291:C781–C787
Bussink J, Kaanders JH, Strik AM, Vojnovic B, van der Kogel AJ (2000) Radiat Res 154:547–555
Xia M, Kodibagkar V, Liu H, Mason RP (2006) Phys Med Biol 51:45–60
Li L, Yu JM, Xing LG, Yang GR, Sun XD, Xu J, Zhu H, Yue JB (2006) Chin Med J (Engl) 119:1477–1480
Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ (1999) J Nucl Med 40:177–183
Baudelet C, Gallez B (2002) Magn Reson Med 48:980–986
Gallez B, Baudelet C, Jordan BF (2004) NMR Biomed 17:240–262
Hunjan S, Zhao D, Constantinescu A, Hahn EW, Antich PP, Mason RP (2001) Int J Radiat Oncol Biol Phys 49:1097–1108
Kodibagkar VD, Wang X, Pacheco-Torres J, Gulaka P, Mason RP (2008) NMR Biomed 21:899–907
Kedderis GL, Miwa GT (1988) Drug Metab Rev 19:33–62
Brown JM (1975) Radiat Res 64:633–647
Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, Wester HJ, Beck R, McEwan AJ, Wiebe LI, Schwaiger M (2005) J Nucl Med 46:106–113
Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG, Karp JS, Alavi A, Lord EM, Dolbier WR Jr, Koch CJ (2000) J Nucl Med 41:327–336
Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, Podoloff DA (1995) Radiology 194:795–800
Lewis J, Laforest R, Buettner T, Song S, Fujibayashi Y, Connett J, Welch M (2001) Proc Natl Acad Sci USA 98:1206–1211
Procissi D, Claus F, Burgman P, Koziorowski J, Chapman JD, Thakur SB, Matei C, Ling CC, Koutcher JA (2007) Clin Cancer Res 13:3738–3747
Rojas-Quijano FA, Tircso G, Tircsone Benyo E, Baranyai Z, Tran Hoang H, Kalman FK, Gulaka PK, Kodibagkar VD, Aime S, Kovacs Z, Sherry AD (2012) Chemistry 18:9669–9676
Zhao D, Ran S, Constantinescu A, Hahn EW, Mason RP (2003) Neoplasia 5:308–318
Aime S, Crich SG, Gianolio E, Giovenzana GB, Tei L, Terreno E (2006) Coord Chem Rev 250:1562–1579
Sherry AD, Brown RD, Geraldes CFG, Koenig SH, Kuan KT, Spiller M (1989) Inorg Chem 28:620–622
Aime S, Anelli PL, Botta M, Fedeli F, Grandi M, Paoli P, Uggeri F (1992) Inorg Chem 31:2422–2428
Norman TJ, Smith FC, Parker D, Harrison A, Royle L, Walker CA (1995) Supramol Chem 4:305–308
Das T, Chakraborty S, Banerjee S, Mukherjee A, Samuel G, Sarma HD, Nair CK, Kagiya VT, Venkatesh M (2004) Bioorg Med Chem 12:6077–6084
Hoigebazar L, Jeong JM, Choi SY, Choi JY, Shetty D, Lee YS, Lee DS, Chung JK, Lee MC, Chung YK (2010) J Med Chem 53:6378–6385
Hoigebazar L, Jeong JM, Hong MK, Kim YJ, Lee JY, Shetty D, Lee YS, Lee DS, Chung JK, Lee MC (2011) Bioorg Med Chem 19:2176–2181
Jiang L, Zhao D, Constantinescu A, Mason RP (2004) Magn Reson Med 51:953–960
Davis SC, Samkoe KS, Tichauer KM, Sexton KJ, Gunn JR, Deharvengt SJ, Hasan T, Pogue BW (2013) Proc Natl Acad Sci USA 110:9025–9030
Vaupel P, Kallinowski F, Okunieff P (1989) Cancer Res 49:6449–6465
Fluckiger JU, Loveless ME, Barnes SL, Lepage M, Yankeelov TE (2013) Phys Med Biol 58:1983–1998
Egeland TA, Gulliksrud K, Gaustad JV, Mathiesen B, Rofstad EK (2012) Magn Reson Med 67:519–530
Terreno E, Geninatti Crich S, Belfiore S, Biancone L, Cabella C, Esposito G, Manazza AD, Aime S (2006) Magn Reson Med 55:491–497
Gianolio E, Arena F, Strijkers GJ, Nicolay K, Högset A, Aime S (2011) Magn Reson Med 65:212–219
Cho H, Ackerstaff E, Carlin S, Lupu ME, Wang Y, Rizwan A, O’Donoghue J, Ling CC, Humm JL, Zanzonico PB, Koutcher JA (2009) Neoplasia 11:247–259
Acknowledgments
This research was supported in part by grants from the Norman Hackerman ARP grant (010019-0056-2007), the National Institutes of Health (R21CA132096, R01CA139043 and R01CA115531), the Southwestern Small Animal Imaging Research Program (U24 CA126608), and the Robert A. Welch Foundation (AT-584). MRI experiments were performed at the Advanced Imaging Research Center with support from a National Institutes of Health National Institute of Biomedical Imaging and Bioengineering resource grant (P41EB015908). We would like to thank Li Liu and Abhijit Bugde for helpful advice.
Author information
Authors and Affiliations
Corresponding author
Additional information
Responsible Editor: Valerie C. Pierre.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Gulaka, P.K., Rojas-Quijano, F., Kovacs, Z. et al. GdDO3NI, a nitroimidazole-based T 1 MRI contrast agent for imaging tumor hypoxia in vivo. J Biol Inorg Chem 19, 271–279 (2014). https://doi.org/10.1007/s00775-013-1058-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-013-1058-5